Evidence map›Paper›PMID 41946684›Full record

ArticleCell death & disease2026

Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models.

Francesca Pedrolli, Giulia Morello, Iacopo Gesmundo, Dana Banfi, Alma Ferro, Medhi Wangpaichitr, Wei Sha, Elena Tamagno, Andrew V Schally, Michela Guglielmotto and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francesca Pedrolli *Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Giulia Morello *Department of Neurosciences "Rita Levi Montalcini", University of Turin and Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Iacopo GesmundoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0003-4901-4764
Dana BanfiDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Alma FerroDepartment of Neurosciences "Rita Levi Montalcini", University of Turin and Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Medhi WangpaichitrMiami VA Healthcare System, Endocrine and Polypeptide Institute, Miami, FL, USA.ORCID http://orcid.org/0000-0002-7338-2041
Wei ShaMiami VA Healthcare System, Endocrine and Polypeptide Institute, Miami, FL, USA.ORCID http://orcid.org/0000-0003-4740-2325
Elena TamagnoDepartment of Neurosciences "Rita Levi Montalcini", University of Turin and Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Andrew V SchallyMiami VA Healthcare System, Endocrine and Polypeptide Institute, Miami, FL, USA.
Michela GuglielmottoDepartment of Neurosciences "Rita Levi Montalcini", University of Turin and Neuroscience Institute Cavalieri Ottolenghi, Turin, Italy.
Riccarda GranataDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy. riccarda.granata@unito.it.ORCID http://orcid.org/0000-0003-4164-7313

Funding

Fondazione CRT (CRT Foundation) 106459/2023.1741Fondazione CRT (CRT Foundation) 10683/2023.1759Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 202229X8hWMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 20223WSTY4
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation, and synaptic loss. Existing therapies provide only modest symptomatic relief and fail to slow disease progression. Beyond its role in promoting pituitary growth hormone (GH) secretion, growth hormone-releasing hormone (GHRH) has shown neuroprotective effects in experimental ischemic stroke and spinal muscular atrophy. Here, we explored the therapeutic potential of GHRH and its agonist MR-409 in AD models. In vitro, GHRH(1-44)NH₂ promoted survival, proliferation, and neuronal differentiation of rat hippocampal neural stem cells (NSCs) and human SH-SY5Y neuroblastoma cells under growth factor deprivation and amyloid beta (Aβ)

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesGrowth Hormone-Releasing HormoneNeuroinflammatory DiseasesAnimalsDisease Models, AnimalHumansMaleMiceNeuroprotective AgentsRatsSignal TransductionAmyloid beta-PeptidesGrowth Hormone-Releasing HormoneNeuroprotective Agents

Identifiers

PMID41946684
PMCPMC13187343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.